Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 10/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15052723 | 1.00 | BTN3A1 (0.52) | BTN3A1CYP3A4CYP2C9ELANEHTT | |
| SCHEMBL17198445 | 1.00 | BTN3A1 (0.52) | BTN3A1CYP3A4CYP2C9ELANEHTT | |
| SCHEMBL790348 | 0.88 | BTN3A1 (0.50) | BTN3A1ELANE | |
| SCHEMBL790562 | 0.88 | BTN3A1 (0.42) | BTN3A1ELANEHTT | |
| SCHEMBL16374214 | 0.86 | BTN3A1 (0.55) | BTN3A1CYP3A4CYP2C9ELANEHTT | |
| SCHEMBL524067 | 0.86 | BTN3A1 (0.55) | BTN3A1CYP3A4CYP2C9ELANEHTT | |
| SCHEMBL18067091 | 0.86 | BTN3A1 (0.52) | BTN3A1CYP3A4CYP2C9ELANE | |
| SCHEMBL20248041 | 0.86 | BTN3A1 (0.55) | BTN3A1CYP3A4CYP2C9ELANEHTT | |
| SCHEMBL18067089 | 0.86 | BTN3A1 (0.52) | BTN3A1CYP3A4CYP2C9ELANE | |
| SCHEMBL524066 | 0.86 | BTN3A1 (0.55) | BTN3A1CYP3A4CYP2C9ELANEHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814739-B2 | 2′-ethynyl nucleoside derivatives for treatment of viral infections | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-9814739-B2 | 2′-ethynyl nucleoside derivatives for treatment of viral infections | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20170112868-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-20170112868-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-9605018-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9556216-B2 | 2′-Ethynyl nucleoside derivatives for treatment of viral infections | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556216-B2 | 2′-Ethynyl nucleoside derivatives for treatment of viral infections | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| WO-2014033617-A1 | 2'-ETHYNYL NUCLEOSIDE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | NOVARTIS AG (CH) | 2014-03-06 | — | — | WO | disclosed |
| US-20130281687-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130253181-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS | VERTEX PHARMACEUTICALS INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253181-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS | VERTEX PHARMACEUTICALS INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013142125-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013096680-A1 | SUBSTITUTED PHOSPHOROTHIOATE NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253181-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS | NUDT1, PNP, TYMP | BTN3A1 4018/4885CYP3A4 3081/4885CYP2C9 3517/4885 |
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | BTN3A1 3276/4885CYP3A4 2267/4885CYP2C9 3190/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | BTN3A1 3215/4885CYP3A4 4180/4885CYP2C9 4386/4885 |
| US-20130281687-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOTIDE ANALOGS | NUDT1, PNP, TYMP | BTN3A1 4018/4885CYP3A4 3081/4885CYP2C9 3517/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | BTN3A1 3215/4885CYP3A4 4180/4885CYP2C9 4386/4885 |
| US-20170112868-A1 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections | EIF2AK2, NEK5, ERN2 | BTN3A1 1740/4885CYP3A4 3134/4885CYP2C9 1981/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | BTN3A1 3276/4885CYP3A4 2267/4885CYP2C9 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.